Background
In comparison to other cancers, gliomas are locally invasive cancers that seldom metastasize. Glioma cells infiltrate brain parenchyma up to several centimeters from the tumor core. Therefore, their recurrence occurs at the margin of tumor resection in about 90% of patients (1). Significant effort is put into analyzing peritumoral regions to understand the mechanisms of glioma recurrence after surgery (1–4). Such studies are done on peritumoral biopsies collected either before or during surgery. This comment seems incidental but is critical.
Surgical Brain Injury Reshapes the Peritumoral Landscape
A critical overlooked point in neurooncology is that brain surgery triggers a wound–healing–inflammatory process in the resection margins where residual glioma cells are. Glioma resection is lesional, and it generates dramatic rearrangements in the peritumoral brain region. The protumorigenic role of wounds and the vicious connection between inflammation and cancer have long been established in other tissues (5, 6). Regarding brain tissue, we already know that in the minutes following cortical and parenchymal incisions, surgical brain injury (SBI) induces (i) a burst of glutamate and ATP, (ii) the release of mutagenic reactive oxygen species, and (iii) an influx of blood clotting factors and serum components (7, 8). Fibroblasts, mesenchymal stem cells, and other blood-borne cells, including inflammatory cells, also invade the resection margin (7, 8). This in turn leads to a further release of cytokines and growth factors. Small ischemic areas around the resection cavity, which are an important driver for malignant progression, are also observed (9, 10). Hallmarks of this perilesional region include inflammation, angiogenesis, glial cell proliferation, reactive gliosis, and fibrosis (7, 8). Indeed, SBI reshapes the peritumoral landscape into a protumorigenic environment.
Conclusion
Peritumoral biopsies collected before or during surgery are not representative of the SBI-induced protumorigenic microenvironment. Hence, critical information is missing to understand and prevent tumor recurrence. Personalized medicine and targeted therapies must integrate new technologies to improve our understanding of the SBI zone. Considering the resection margins as peritumoral or as perilesional is more than a simple matter of vocabulary. It is a necessary paradigm shift to understand and treat glioma recurrence after surgery.
Author Contributions
All authors listed, have made substantial, direct, and intellectual contribution to the work, and approved it for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- 1.Lemée J-M, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don’t forget the peritumoral brain zone. Neuro Oncol (2015) 17:1322–32. 10.1093/neuonc/nov119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A (2014) 111:12550–5. 10.1073/pnas.1405839111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Fazi B, Felsani A, Grassi L, Moles A, D’Andrea D, Toschi N, et al. The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. Oncotarget (2015) 6(26):22526–52. 10.18632/oncotarget.4151 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Aubry M, de Tayrac M, Etcheverry A, Clavreul A, Saikali S, Menei P, et al. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget (2015) 6:12094–109. 10.18632/oncotarget.3297 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 35:467–77. 10.1016/j.immuni.2011.09.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2010) 20:65–71. 10.1016/j.gde.2009.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron (2014) 81:229–48. 10.1016/j.neuron.2013.12.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Liu J-M, Mao B-Y, Hong S, Liu Y-H, Wang X-J. The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence. Adv Ther (2008) 25:389–98. 10.1007/s12325-008-0050-x [DOI] [PubMed] [Google Scholar]
- 9.Gempt J, Förschler A, Buchmann N, Pape H, Ryang Y-M, Krieg SM, et al. Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance. J Neurosurg (2013) 118:801–8. 10.3171/2012.12.JNS12125 [DOI] [PubMed] [Google Scholar]
- 10.Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res (2012) 318:2417–26. 10.1016/j.yexcr.2012.07.017 [DOI] [PubMed] [Google Scholar]